Financing
Noncontrolling interest transactions and other
Vertex Pharmaceuticals Noncontrolling interest transactions and other decreased by 136.4% to -$400.00K in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 20.0%, from -$500.00K to -$400.00K. Over 4 years (FY 2021 to FY 2025), Noncontrolling interest transactions and other shows a downward trend with a -10.2% CAGR.
Analysis
StatementCash Flow Statement
SectionFinancing
First reportedQ1 2016
Last reportedQ1 2026May 5, 2026
Metric ID:
lin_noncontrolling_interest_transactions_and_otherHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.60M | $1.40M | $1.40M | $1.30M | $400.00K | $700.00K | $1.10M | $1.10M | $1.10M | $1.10M | $450.00K | $3.50M | $900.00K | $900.00K | $900.00K | -$500.00K | $2.00M | $1.10M | $1.10M | -$400.00K |
| QoQ Change | — | -12.5% | +0.0% | -7.1% | -69.2% | +75.0% | +57.1% | +0.0% | +0.0% | +0.0% | -59.1% | +677.8% | -74.3% | +0.0% | +0.0% | -155.6% | +500.0% | -45.0% | +0.0% | -136.4% |
| YoY Change | — | — | — | — | -75.0% | -50.0% | -21.4% | -15.4% | +175.0% | +57.1% | -59.1% | +218.2% | -18.2% | -18.2% | +100.0% | -114.3% | +122.2% | +22.2% | +22.2% | +20.0% |
Range-$500.00K – $3.50M
CAGR-25.3%
Avg YoY Growth+22.8%
Median YoY Growth+2.3%
Noncontrolling interest transactions and other at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's noncontrolling interest transactions and other?
- Vertex Pharmaceuticals (VRTX) reported noncontrolling interest transactions and other of -$400.00K in Q1 2026.
- How has Vertex Pharmaceuticals's noncontrolling interest transactions and other changed year-over-year?
- Vertex Pharmaceuticals's noncontrolling interest transactions and other increased by 20.0% year-over-year, from -$500.00K to -$400.00K.
- What is the long-term trend for Vertex Pharmaceuticals's noncontrolling interest transactions and other?
- Over 4 years (2021 to 2025), Vertex Pharmaceuticals's noncontrolling interest transactions and other has grown at a -10.2% compound annual growth rate (CAGR), from $5.70M to $3.70M.